Previous close | 15.70 |
Open | 15.60 |
Bid | 15.60 x 129600 |
Ask | 16.20 x 126400 |
Day's range | 15.60 - 15.60 |
52-week range | 14.00 - 21.00 |
Volume | |
Avg. volume | 12 |
Market cap | 8.507B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 24.00 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.36 (2.31%) |
Ex-dividend date | 27 Jun 2024 |
1y target est | N/A |
TOKYO, April 15, 2024--On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, "Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)", a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subt
Kyowa Kirin Co., Ltd. (TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, today announced that pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD), will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to b
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product in patients with moderate-to-severe atopic dermatitis (msAD), will be presented at the American Academy of Dermatology (AAD) 2024 Annual Meeting to be held in San Diego from March 8-12, 2024.